{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:53:43Z","timestamp":1792155223198,"version":"4.4.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,11,11]],"date-time":"2018-11-11T00:00:00Z","timestamp":1541894400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,11,11]],"date-time":"2018-11-11T00:00:00Z","timestamp":1541894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA091846"],"award-info":[{"award-number":["P50CA091846"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00345-018-2553-7","type":"journal-article","created":{"date-parts":[[2018,11,11]],"date-time":"2018-11-11T03:15:41Z","timestamp":1541906141000},"page":"2041-2049","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside"],"prefix":"10.1007","volume":"37","author":[{"given":"Jonathan J.","family":"Duplisea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharada","family":"Mokkapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Plote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly S.","family":"Schluns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"McConkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seppo","family":"Yla-Herttuala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel R.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin P.","family":"Dinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,11]]},"reference":[{"issue":"9685","key":"2553_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/s0140-6736(09)60491-8","volume":"374","author":"DS Kaufman","year":"2009","unstructured":"Kaufman DS, Shipley WU, Feldman AS (2009) Bladder cancer. Lancet (Lond, Engl) 374(9685):239\u2013249. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(09)60491-8","journal-title":"Lancet (Lond, Engl)"},{"issue":"1","key":"2553_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A (2017) Cancer statistics 2017. CA Cancer J Clin 67(1):7\u201330. \n                    https:\/\/doi.org\/10.3322\/caac.21387","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2553_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, Hernandez V, Kaasinen E, Palou J, Roupret M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71(3):447\u2013461. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2016.05.041","journal-title":"Eur Urol"},{"issue":"4","key":"2553_CR4","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol 196(4):1021\u20131029. \n                    https:\/\/doi.org\/10.1016\/j.juro.2016.06.049","journal-title":"J Urol"},{"issue":"10","key":"2553_CR5","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.6004\/jnccn.2017.0156","volume":"15","author":"PE Spiess","year":"2017","unstructured":"Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA (2017) Bladder cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Nat Compr Cancer Netw JNCCN 15(10):1240\u20131267. \n                    https:\/\/doi.org\/10.6004\/jnccn.2017.0156","journal-title":"J Nat Compr Cancer Netw JNCCN"},{"issue":"2","key":"2553_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3233\/blc-150016","volume":"1","author":"J Jarow","year":"2015","unstructured":"Jarow J, Maher VE, Tang S, Ibrahim A, Kim G, Sridhara R, Pazdur R (2015) Development of systemic and topical drugs to treat non-muscle invasive bladder cancer. Bladder Cancer (Amst, Neth) 1(2):133\u2013136. \n                    https:\/\/doi.org\/10.3233\/blc-150016","journal-title":"Bladder Cancer (Amst, Neth)"},{"issue":"4","key":"2553_CR7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S0022-5347(17)51400-7","volume":"130","author":"GR Prout Jr","year":"1983","unstructured":"Prout GR Jr, Koontz WW Jr, Coombs LJ, Hawkins IR, Friedell GH (1983) Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. J Urol 130(4):677\u2013680","journal-title":"J Urol"},{"issue":"3","key":"2553_CR8","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","volume":"163","author":"G Steinberg","year":"2000","unstructured":"Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M (2000) Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 163(3):761\u2013767","journal-title":"J Urol"},{"issue":"4","key":"2553_CR9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nrurol.2017.16","volume":"14","author":"AM Kamat","year":"2017","unstructured":"Kamat AM, Colombel M, Sundi D, Lamm D, Boehle A, Brausi M, Buckley R, Persad R, Palou J, Soloway M, Witjes JA (2017) BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nat Rev Urol 14(4):244\u2013255. \n                    https:\/\/doi.org\/10.1038\/nrurol.2017.16","journal-title":"Nat Rev Urol"},{"issue":"2","key":"2553_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3233\/blc-150039","volume":"2","author":"RL Steinberg","year":"2016","unstructured":"Steinberg RL, Thomas LJ, Mott SL, O\u2019Donnell MA (2016) Bacillus Calmette-Guerin (BCG) treatment failures with non-muscle invasive bladder cancer: a data-driven definition for BCG unresponsive disease. Bladder Cancer (Amst, Neth) 2(2):215\u2013224. \n                    https:\/\/doi.org\/10.3233\/blc-150039","journal-title":"Bladder Cancer (Amst, Neth)"},{"issue":"6 Suppl 1","key":"2553_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.urology.2005.08.066","volume":"66","author":"AM Nieder","year":"2005","unstructured":"Nieder AM, Brausi M, Lamm D, O\u2019Donnell M, Tomita K, Woo H, Jewett MA (2005) Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 66(6 Suppl 1):108\u2013125. \n                    https:\/\/doi.org\/10.1016\/j.urology.2005.08.066","journal-title":"Urology"},{"issue":"1","key":"2553_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/blc-159002","volume":"1","author":"SP Lerner","year":"2015","unstructured":"Lerner SP, Dinney C, Kamat A, Bivalacqua TJ, Nielsen M, O\u2019Donnell M, Schoenberg MP, Steinberg G (2015) Clarification of bladder cancer disease states following treatment of patients with intravesical BCG. Bladder Cancer (Amster, Neth) 1(1):29\u201330. \n                    https:\/\/doi.org\/10.3233\/blc-159002","journal-title":"Bladder Cancer (Amster, Neth)"},{"key":"2553_CR13","unstructured":"US Department of Health and Human Service Food and Drug administration (2018) BCG unresponsive non-muscle invasive bladder cancer\u2014developing drugs and biologics for treatment\u2014a guideline for industry. \n                    https:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/CellularandgeneTherapy\/default\/htm"},{"issue":"8","key":"2553_CR14","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.urolonc.2017.06.043","volume":"35","author":"MR Siddiqui","year":"2017","unstructured":"Siddiqui MR, Grant C, Sanford T, Agarwal PK (2017) Current clinical trials in non-muscle invasive bladder cancer. Urol Oncol 35(8):516\u2013527. \n                    https:\/\/doi.org\/10.1016\/j.urolonc.2017.06.043","journal-title":"Urol Oncol"},{"issue":"6","key":"2553_CR15","doi-asserted-by":"publisher","first-page":"872","DOI":"10.4161\/cbt.6.6.4088","volume":"6","author":"A Papageorgiou","year":"2007","unstructured":"Papageorgiou A, Dinney CP, McConkey DJ (2007) Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells. Cancer Biol Ther 6(6):872\u2013879","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"2553_CR16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/jnci\/95.6.437","volume":"95","author":"Z von Marschall","year":"2003","unstructured":"von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, Oberg K, Wiedenmann B, Hocker M, Rosewicz S (2003) Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 95(6):437\u2013448","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2553_CR17","first-page":"808","volume":"58","author":"CP Dinney","year":"1998","unstructured":"Dinney CP, Bielenberg DR, Perrotte P, Reich R, Eve BY, Bucana CD, Fidler IJ (1998) Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Can Res 58(4):808\u2013814","journal-title":"Can Res"},{"issue":"10","key":"2553_CR18","first-page":"2726","volume":"5","author":"JW Slaton","year":"1999","unstructured":"Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ (1999) Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5(10):2726\u20132734","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2553_CR19","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","volume":"24","author":"FN Joudi","year":"2006","unstructured":"Joudi FN, Smith BJ, O\u2019Donnell MA (2006) Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24(4):344\u2013348. \n                    https:\/\/doi.org\/10.1016\/j.urolonc.2005.11.026","journal-title":"Urol Oncol"},{"issue":"1","key":"2553_CR20","doi-asserted-by":"publisher","first-page":"35.e21","DOI":"10.1016\/j.urolonc.2013.02.010","volume":"32","author":"D Lamm","year":"2014","unstructured":"Lamm D, Brausi M, O\u2019Donnell MA, Witjes JA (2014) Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. Urol Oncol 32(1):35.e21\u201335.e30. \n                    https:\/\/doi.org\/10.1016\/j.urolonc.2013.02.010","journal-title":"Urol Oncol"},{"issue":"7","key":"2553_CR21","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1046\/j.1464-410X.2002.02734.x","volume":"89","author":"PU Malmstrom","year":"2002","unstructured":"Malmstrom PU (2002) A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder. BJU Int 89(7):681\u2013686","journal-title":"BJU Int"},{"issue":"3","key":"2553_CR22","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1097\/01.ju.0000026417.33622.7d","volume":"168","author":"P Rajala","year":"2002","unstructured":"Rajala P, Kaasinen E, Raitanen M, Liukkonen T, Rintala E (2002) Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study\u2013FinnBladder III long-term results. J Urol 168(3):981\u2013985. \n                    https:\/\/doi.org\/10.1097\/01.ju.0000026417.33622.7d","journal-title":"J Urol"},{"issue":"3","key":"2553_CR23","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1200\/jco.1988.6.3.476","volume":"6","author":"FM Torti","year":"1988","unstructured":"Torti FM, Shortliffe LD, Williams RD, Pitts WC, Kempson RL, Ross JC, Palmer J, Meyers F, Ferrari M, Hannigan J et al (1988) Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study. J Clin Oncol 6(3):476\u2013483. \n                    https:\/\/doi.org\/10.1200\/jco.1988.6.3.476","journal-title":"J Clin Oncol"},{"key":"2553_CR24","doi-asserted-by":"publisher","first-page":"656918","DOI":"10.1155\/2015\/656918","volume":"2015","author":"AF Correa","year":"2015","unstructured":"Correa AF, Theisen K, Ferroni M, Maranchie JK, Hrebinko R, Davies BJ, Gingrich JR (2015) The role of interferon in the management of BCG refractory nonmuscle invasive bladder cancer. Adv Urol 2015:656918. \n                    https:\/\/doi.org\/10.1155\/2015\/656918","journal-title":"Adv Urol"},{"key":"2553_CR25","doi-asserted-by":"publisher","first-page":"Cd012112","DOI":"10.1002\/14651858.cd012112.pub2","volume":"3","author":"AR Shepherd","year":"2017","unstructured":"Shepherd AR, Shepherd E, Brook NR (2017) Intravesical Bacillus Calmette-Guerin with interferon-alpha versus intravesical Bacillus Calmette-Guerin for treating non-muscle-invasive bladder cancer. Cochrane Database Syst Rev 3:Cd012112. \n                    https:\/\/doi.org\/10.1002\/14651858.cd012112.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2553_CR26","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/S0022-5347(01)63160-4","volume":"159","author":"AS Belldegrun","year":"1998","unstructured":"Belldegrun AS, Franklin JR, O\u2019Donnell MA, Gomella LG, Klein E, Neri R, Nseyo UO, Ratliff TL, Williams RD (1998) Superficial bladder cancer: the role of interferon-alpha. J Urol 159(6):1793\u20131801","journal-title":"J Urol"},{"issue":"5","key":"2553_CR27","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/jama.285.5.545","volume":"285","author":"EH Kaji","year":"2001","unstructured":"Kaji EH, Leiden JM (2001) Gene and stem cell therapies. JAMA 285(5):545\u2013550","journal-title":"JAMA"},{"issue":"6","key":"2553_CR28","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/cco.0000000000000004","volume":"25","author":"W Walther","year":"2013","unstructured":"Walther W, Schlag PM (2013) Current status of gene therapy for cancer. Curr Opin Oncol 25(6):659\u2013664. \n                    https:\/\/doi.org\/10.1097\/cco.0000000000000004","journal-title":"Curr Opin Oncol"},{"issue":"9","key":"2553_CR29","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1056\/nejm199008303230904","volume":"323","author":"SA Rosenberg","year":"1990","unstructured":"Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL et al (1990) Gene transfer into humans\u2013immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323(9):570\u2013578. \n                    https:\/\/doi.org\/10.1056\/nejm199008303230904","journal-title":"N Engl J Med"},{"issue":"2","key":"2553_CR30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.gene.2013.03.137","volume":"525","author":"T Wirth","year":"2013","unstructured":"Wirth T, Parker N, Yla-Herttuala S (2013) History of gene therapy. Gene 525(2):162\u2013169. \n                    https:\/\/doi.org\/10.1016\/j.gene.2013.03.137","journal-title":"Gene"},{"issue":"10","key":"2553_CR31","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1517\/14712598.4.10.1595","volume":"4","author":"PJ Wysocki","year":"2004","unstructured":"Wysocki PJ, Karczewska-Dzionk A, Mackiewicz-Wysocka M, Mackiewicz A (2004) Human cancer gene therapy with cytokine gene-modified cells. Expert Opin Biol Ther 4(10):1595\u20131607. \n                    https:\/\/doi.org\/10.1517\/14712598.4.10.1595","journal-title":"Expert Opin Biol Ther"},{"issue":"11","key":"2553_CR32","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s40264-014-0226-z","volume":"37","author":"BA Baldo","year":"2014","unstructured":"Baldo BA (2014) Side effects of cytokines approved for therapy. Drug Saf 37(11):921\u2013943. \n                    https:\/\/doi.org\/10.1007\/s40264-014-0226-z","journal-title":"Drug Saf"},{"issue":"1","key":"2553_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1634\/theoncologist.6-1-34","volume":"6","author":"E Jonasch","year":"2001","unstructured":"Jonasch E, Haluska FG (2001) Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6(1):34\u201355","journal-title":"Oncologist"},{"issue":"2","key":"2553_CR34","first-page":"97","volume":"2","author":"C Bass","year":"1995","unstructured":"Bass C, Cabrera G, Elgavish A, Robert B, Siegal GP, Anderson SC, Maneval DC, Curiel DT (1995) Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo. Cancer Gene Ther 2(2):97\u2013104","journal-title":"Cancer Gene Ther"},{"issue":"Suppl 1","key":"2553_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5301\/uro.5000184","volume":"83","author":"CH Klingler","year":"2016","unstructured":"Klingler CH (2016) Glycosaminoglycans: how much do we know about their role in the bladder? Urologia 83(Suppl 1):11\u201314. \n                    https:\/\/doi.org\/10.5301\/uro.5000184","journal-title":"Urologia"},{"issue":"5","key":"2553_CR36","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0090-4295(98)00641-4","volume":"53","author":"H Engler","year":"1999","unstructured":"Engler H, Anderson SC, Machemer TR, Philopena JM, Connor RJ, Wen SF, Maneval DC (1999) Ethanol improves adenovirus-mediated gene transfer and expression to the bladder epithelium of rodents. Urology 53(5):1049\u20131053","journal-title":"Urology"},{"issue":"1","key":"2553_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/sj.gt.3301348","volume":"8","author":"RJ Connor","year":"2001","unstructured":"Connor RJ, Engler H, Machemer T, Philopena JM, Horn MT, Sutjipto S, Maneval DC, Youngster S, Chan TM, Bausch J, McAuliffe JP, Hindsgaul O, Nagabhushan TL (2001) Identification of polyamides that enhance adenovirus-mediated gene expression in the urothelium. Gene Ther 8(1):41\u201348. \n                    https:\/\/doi.org\/10.1038\/sj.gt.3301348","journal-title":"Gene Ther"},{"issue":"8","key":"2553_CR38","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/sj.cgt.7700488","volume":"9","author":"M Yamashita","year":"2002","unstructured":"Yamashita M, Rosser CJ, Zhou JH, Zhang XQ, Connor RJ, Engler H, Maneval DC, Karashima T, Czerniak BA, Dinney CP, Benedict WF (2002) Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Cancer Gene Ther 9(8):687\u2013691. \n                    https:\/\/doi.org\/10.1038\/sj.cgt.7700488","journal-title":"Cancer Gene Ther"},{"issue":"10","key":"2553_CR39","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/sj.cgt.7700364","volume":"8","author":"CM Iqbal Ahmed","year":"2001","unstructured":"Iqbal Ahmed CM, Johnson DE, Demers GW, Engler H, Howe JA, Wills KN, Wen SF, Shinoda J, Beltran J, Nodelman M, Machemer T, Maneval DC, Nagabhushan TL, Sugarman BJ (2001) Interferon alpha2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers. Cancer Gene Ther 8(10):788\u2013795. \n                    https:\/\/doi.org\/10.1038\/sj.cgt.7700364","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"2553_CR40","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.ymthe.2004.05.027","volume":"10","author":"WF Benedict","year":"2004","unstructured":"Benedict WF, Tao Z, Kim CS, Zhang X, Zhou JH, Adam L, McConkey DJ, Papageorgiou A, Munsell M, Philopena J, Engler H, Demers W, Maneval DC, Dinney CP, Connor RJ (2004) Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther J Am Soc Gene Ther 10(3):525\u2013532. \n                    https:\/\/doi.org\/10.1016\/j.ymthe.2004.05.027","journal-title":"Mol Ther J Am Soc Gene Ther"},{"issue":"4","key":"2553_CR41","first-page":"1258","volume":"8","author":"JI Izawa","year":"2002","unstructured":"Izawa JI, Sweeney P, Perrotte P, Kedar D, Dong Z, Slaton JW, Karashima T, Inoue K, Benedict WF, Dinney CP (2002) Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res 8(4):1258\u20131270","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2553_CR42","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/cgt.2014.1","volume":"21","author":"WF Benedict","year":"2014","unstructured":"Benedict WF, Fisher M, Zhang XQ, Yang Z, Munsell MF, Dinney CN (2014) Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNalpha\/Syn3 treatment in a phase l study. Cancer Gene Ther 21(3):91\u201394. \n                    https:\/\/doi.org\/10.1038\/cgt.2014.1","journal-title":"Cancer Gene Ther"},{"issue":"12","key":"2553_CR43","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/cgt.2008.53","volume":"15","author":"X Zhang","year":"2008","unstructured":"Zhang X, Dong L, Chapman E, Benedict WF (2008) Conditioned medium from Ad-IFN-alpha-infected bladder cancer and normal urothelial cells is cytotoxic to cancer cells but not normal cells: further evidence for a strong bystander effect. Cancer Gene Ther 15(12):817\u2013822. \n                    https:\/\/doi.org\/10.1038\/cgt.2008.53","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"2553_CR44","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/sj.cgt.7701011","volume":"14","author":"X Zhang","year":"2007","unstructured":"Zhang X, Yang Z, Dong L, Papageorgiou A, McConkey DJ, Benedict WF (2007) Adenoviral-mediated interferon alpha overcomes resistance to the interferon protein in various cancer types and has marked bystander effects. Cancer Gene Ther 14(3):241\u2013250. \n                    https:\/\/doi.org\/10.1038\/sj.cgt.7701011","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"2553_CR45","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.urology.2005.02.015","volume":"66","author":"RJ Connor","year":"2005","unstructured":"Connor RJ, Anderson JM, Machemer T, Maneval DC, Engler H (2005) Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens. Urology 66(1):224\u2013229. \n                    https:\/\/doi.org\/10.1016\/j.urology.2005.02.015","journal-title":"Urology"},{"issue":"2","key":"2553_CR46","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/sj.cgt.7700865","volume":"13","author":"Z Tao","year":"2006","unstructured":"Tao Z, Connor RJ, Ashoori F, Dinney CP, Munsell M, Philopena JA, Benedict WF (2006) Efficacy of a single intravesical treatment with Ad-IFN\/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation. Cancer Gene Ther 13(2):125\u2013130. \n                    https:\/\/doi.org\/10.1038\/sj.cgt.7700865","journal-title":"Cancer Gene Ther"},{"issue":"4","key":"2553_CR47","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1089\/hum.2014.007","volume":"25","author":"J Vellinga","year":"2014","unstructured":"Vellinga J, Smith JP, Lipiec A, Majhen D, Lemckert A, van Ooij M, Ives P, Yallop C, Custers J, Havenga M (2014) Challenges in manufacturing adenoviral vectors for global vaccine product deployment. Hum Gene Ther 25(4):318\u2013327. \n                    https:\/\/doi.org\/10.1089\/hum.2014.007","journal-title":"Hum Gene Ther"},{"issue":"3","key":"2553_CR48","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.juro.2013.03.030","volume":"190","author":"CP Dinney","year":"2013","unstructured":"Dinney CP, Fisher MB, Navai N, O\u2019Donnell MA, Cutler D, Abraham A, Young S, Hutchins B, Caceres M, Kishnani N, Sode G, Cullen C, Zhang G, Grossman HB, Kamat AM, Gonzales M, Kincaid M, Ainslie N, Maneval DC, Wszolek MF, Benedict WF (2013) Phase I trial of intravesical recombinant adenovirus mediated interferon-alpha2b formulated in Syn3 for Bacillus Calmette-Guerin failures in nonmuscle invasive bladder cancer. J Urol 190(3):850\u2013856. \n                    https:\/\/doi.org\/10.1016\/j.juro.2013.03.030","journal-title":"J Urol"},{"issue":"30","key":"2553_CR49","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1200\/jco.2017.72.3064","volume":"35","author":"ND Shore","year":"2017","unstructured":"Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb RL 3rd, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G, Sawutz DG, Yla-Herttuala S, Parker NR, Dinney CPN (2017) Intravesical rAd-IFNalpha\/Syn3 for patients with high-grade, Bacillus Calmette-Guerin-refractory or relapsed non-muscle-invasive bladder cancer: a Phase II Randomized Study. J Clin Oncol 35(30):3410\u20133416. \n                    https:\/\/doi.org\/10.1200\/jco.2017.72.3064","journal-title":"J Clin Oncol"},{"issue":"8","key":"2553_CR50","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","volume":"31","author":"CP Dinney","year":"2013","unstructured":"Dinney CP, Greenberg RE, Steinberg GD (2013) Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin. Urol Oncol 31(8):1635\u20131642. \n                    https:\/\/doi.org\/10.1016\/j.urolonc.2012.04.010","journal-title":"Urol Oncol"},{"key":"2553_CR51","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.urolonc.2017.07.005","volume":"45","author":"VT Packiam","year":"2017","unstructured":"Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL 3rd, Clark W, Kroeger M, Dumbadze I, Chamie K, Kader AK, Curran D, Gutheil J, Kuan A, Yeung AW, Steinberg GD (2017) An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results. Urol Oncol 45:54. \n                    https:\/\/doi.org\/10.1016\/j.urolonc.2017.07.005","journal-title":"Urol Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-018-2553-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-018-2553-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-018-2553-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T12:23:23Z","timestamp":1589631803000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-018-2553-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,11]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["2553"],"URL":"https:\/\/doi.org\/10.1007\/s00345-018-2553-7","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,11]]},"assertion":[{"value":"5 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Nigel Parker: leadership, consulting, and research funding\u2014FKD Therapies Oy. Seppo Yla-Herttulla: consultant for FKD Therapies Oy. Colin Dinney: consultant on advisory board for FKD Therapies Oy. All remaining authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Informed consent was obtained from all individual participants of clinical studies included in this review article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}